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Abstract
Infection with the Epstein-Barr virus (EBV) is a strong predisposing factor in the development of nasopharyngeal
carcinoma (NPC). Many viral gene products including EBNA1, LMP1, and LMP2 have been implicated in NPC tumori-
genesis, although the de novo control of these viral oncoproteins remains largely unclear. The recent discovery of
EBV-encoded viral microRNA (miRNA) in lymphoid malignancies has prompted us to examine the NPC-associated
EBV miRNA. Using large-scale cloning analysis on EBV-positive NPC cells, two novel EBV miRNA, now named miR-
BART21 and miR-BART22, were identified. These two EBV-encoded miRNA are abundantly expressed in most NPC
samples. We found two nucleotide variations in the primary transcript of miR-BART22, which we experimentally
confirmed to augment its biogenesis in vitro and thus may underline the high and consistent expression of miR-
BART22 in NPC tumors. More importantly, we determined that the EBV latent membrane protein 2A (LMP2A) is
the putative target of miR-BART22. LMP2A is a potent immunogenic viral antigen that is recognized by the cytotoxic
T cells; down-modulation of LMP2A expression by miR-BART22 may permit escape of EBV-infected cells from host
immune surveillance. Taken together, we demonstrated that two newly identified EBV-encoded miRNA are highly
expressed in NPC. Specific sequence variations on the prevalent EBV strain in our locality might contribute to the
higher miR-BART22 expression level in our NPC samples. Our findings emphasize the role of miR-BART22 in modu-
lating LMP2A expression, which may facilitate NPC carcinogenesis by evading the host immune response.
Neoplasia (2009) 11, 1174–1184
Introduction
MicroRNA (miRNA) are a group of small, noncoding RNAwith a size
of approximately 18 to 24 nucleotides. They are produced by en-
dogenous enzymatic (Drosha/DGCR8 and Dicer) digestion of RNA
transcripts containing hairpin structure. Mature miRNA function as
negative gene regulators through complementary sequence pairing to
the 3′ untranslated region (3′UTR) of the target gene by inducing either
messenger RNA (mRNA) degradation or translational repression [1]. As
gene regulators, mammalian miRNA play key roles not only in various
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biological processes including development and differentiation but also
in cancer development.
Infection with the Epstein-Barr virus (EBV) is common among
most adults worldwide. Whereas most people will recover from the
symptoms of acute infection, latent infection with EBV is known to be
associated with a number of lymphoid and epithelial malignancies,
such as Hodgkin disease (HD), Burkitt lymphoma, nasopharyngeal
carcinoma (NPC), and a subset of gastric carcinoma. The epithelial
cancer NPC is uniquely prevalent in Southern China. Clonal EBV
genomes can be detected in both high-grade dysplastic lesions and
invasive carcinoma, implying an important etiologic role for EBV in
NPC carcinogenesis [2]. EBV resides in NPC as latency II infection,
where only few viral latent proteins including EBV nuclear antigen 1
(EBNA1) and latentmembrane proteins 1 and 2A (LMP1 and LMP2A)
are expressed. These viral proteins have thus been proposed in the NPC
development by their disruption of multiple signaling pathways and
cellular mechanisms [3]. Two types of noncoding RNA, EBV-encoded
RNA (EBERs) and BamH1-A rightward transcripts (BARTs), are
expressed in EBV-positive NPC cells. EBERs are small, nonpolyadeny-
lated RNA that are consistently expressed in all forms of viral latency.
BARTs are multispliced transcripts that were originally discovered in
NPC and later reported in other EBV-infected individuals [4–6]. Be-
cause expression of BARTs is selectively high in EBV-positive NPC
and gastric cancer cells, it has been long speculated that BARTs have
important functional roles in these EBV-associated epithelial malig-
nancies [7]. Recent studies on viral miRNA have identified 23 EBV
miRNA (ebv-miRNA) from latently infected B cells [7–9]. Among
them, 20 miRNA (miR-BART1 to miR-BART20) are located in two
clusters within the BARTs region, which is generally highly expressed
in most EBV infected epithelial cells [7]. Because only a few viral latent
proteins are expressed in NPC, it is plausible that EBVaugments cancer
development through its viral-encoded miRNA. Whereas in most in-
stances the function of these EBV-miRNA remains unknown, recent
discoveries suggest much importance for miR-BARTs in modulating
both viral and cellular gene expressions [10,11]. In line with these re-
ports, our group has recently demonstrated that miR-BART1, 16,
and 17 can regulate the LMP1 viral oncogene expression in NPC by
translational repression [12]. Furthermore, miR-BART5 can alter the
expression of the p53–upregulated modulator of apoptosis (PUMA),
which promotes NPC cell survival [13]. On the basis of perfect comple-
mentary to the 3′UTR of BALF5 mRNA, miR-BART2 could down-
regulate this viral lytic protein production by mRNA degradation [14].
Whereas miR-BARTs hold much importance in complex virus-
host interactions and contribute to human carcinogenesis, currently
identified ebv-miRNA were cloned from EBV-positive lymphoma
cell lines and confirmed for expression in these cell lines after com-
putational prediction from the EBV sequence [7–9]. Thus, EBV-
encoded miRNA involved in NPC may have escaped detection in
previous discovery processes. In this study, we have systemically ex-
amined the NPC-associated EBV genome for viral-encoded miRNA
expression. By constructing a small complementary DNA (cDNA)
library from a native EBV-positive NPC cell line (C666-1) and a
xenograft (X2117), we identified within the BARTs region two novel
ebv-miRNA, which now named miR-BART21 and miR-BART22.
We found that these two miRNA are highly expressed in NPC cell
lines, xenografts, and primary tumor biopsies. By comparing se-
quences between different EBV strains, we identified two nucleotide
variations upstream of mature miR-BART22, which have likely favored
its biogenesis by Drosha/DGCR8 processing. This finding could in
part explain the high expression of miR-BART22 in endemic NPC
samples. By bioinformatics analysis and functional screening, we found
that LMP2A, an important viral latent gene, is one of the downstream
targets of miR-BART22. Among all EBV latent genes expressed in
NPC cells, the LMP2A-encoded protein exhibits relatively strong im-
munogenicity toward cytotoxic T cells (CTLs). In this context, LMP2A
expression in NPC is tightly regulated to promote tumor cell survival
by escaping the host immune response. The findings in this report
highlight that specific ebv-miRNA are present in NPC and that miR-
BART22 may well have contributed to NPC development through its
modulation of LMP2A expression.
Materials and Methods
Plasmid Constructs
The renilla luciferase reporter control plasmid, pRL-CMV, and the
enhanced green fluorescence protein (EGFP) expression plasmid,
pEGFP-C1, were purchased from Promega Corp (Madison, WI) and
Clontech (Mountain View, CA), respectively. The LMP2A expression
plasmid contained the complete LMP2AORF + 3′UTR and themiRNA
expression plasmids contained miRNA flanking sequence (∼300 nt).
They were generated by polymerase chain reaction (PCR) and cloned
into the pcDNA3.1 (Invitrogen, Carlsbad, CA). Construction of the
firefly luciferase reporter plasmids by using pMIR-REPORT (Ambion,
Inc, Austin, TX) was described previously [15]. The sequences of the
primers used are listed in SI Methods.
Cell Lines, Xenografts, and Tumor Samples
All cell lines were cultured in RPMI plus 10% FBS unless otherwise
specified. 293FTandHEK293 cells were cultured inminimum essential
medium plus 10% FBS. NP69 and NP460 were grown in keratinocyte
serum-free medium and Defined keratinocyte serum-free medium
(Invitrogen), respectively. All nasopharyngeal (NP), NPC, infectious
mononucleosis (IM), and HD biopsies were obtained from the Prince
of Wales Hospital, of the Chinese University of Hong Kong. The study
was approved by the local ethics committee.
Transfection of HEK293 cells was performed using GeneJuice trans-
fection reagent (Novagen, Madison, WI) following the manufacturer’s
protocol. LMP2A expressing HEK293 stable clones were isolated as
single colonies and selected in medium containing 400 μg/ml of G418
(Invitrogen) for 12 weeks before analysis.
Transfection of siRNA and miRNA Mimic
SiRNA duplexes and miRNA mimics were purchased from Qiagen
(Hilden, Germany). The target sequence of siLMP2Awith dTdTover-
hangs modification was AACUCCCAAUAUCCAUCUGCU [16].
The sequences of the miRNA mimics used are listed in Figure 4B.
Allstars negative control (Qiagen) was used in both siRNA and miRNA
transfection experiments. In the experiments, 20 nM of siRNA and
miRNA mimics were used to transfect cells in six-well plate format.
Protein and RNA were extracted 24 hours after transfection. All trans-
fections were carried out by Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol.
RNA Extraction and Small cDNA Library Construction
Total RNAwas extracted by TRIzol reagent (Invitrogen) without any
ethanol washing step. The enriched small RNA fraction was collected
with miVana miRNA Isolation Kit according to the manufacturer’s in-
structions (Ambion). Twenty micrograms of enriched RNA was used
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for library construction by using the miRCat cloning kit (Integrated
DNA Technologies, Coralville, IA). Sequence analysis was performed
using an ABI PRISM 3130xl DNA Sequencer.
miRNA Identification and RNA Structure Prediction
Isolated RNA fragments longer than 18 nt were annotated to the
genome. Known miRNA were identified by blasting the sequences to
“miRBase” [9]. The remaining sequences were individually blasted to
the National Center for Biotechnology Information databases. Putative
precursor sequences of the cloned EBV fragments were extracted from
the EBV genome (AJ507799) and further examined using theMFOLD
program to predict their pre-miRNA structures [17]. The most stable
predicted structure was trimmed to a size of less than 80 nucleotides.
Northern Blot Analysis
Tenmicrograms total of RNAwas electrophoresed by 12%PAGEand
transferred onto Nytran SPC membrane (Whatman, Inc, Piscataway,
NJ) for blot analysis. Oligonucleotides complementary to the mature
miRNA were end-labeled with (γ-32P) as a probe. Hybridization was
performed in ULTRAhyb-Oligo hybridization buffer (Ambion). The
sequences of the probes are listed in SI Methods. The density of the
Northern blot signal was measured by Image J software (download from
http://rsb.info.nih.gov/ij/).
Quantitative Reverse Transcription–Polymerase
Chain Reaction
For normal reverse transcription–polymerase chain reaction (RT-
PCR), 1 μg of RNA was reverse-transcribed with Superscript III using
random primers (Invitrogen), and quantitative RT-PCR (QRT-PCR)
products were amplified by using the SYBR Green PCR Master Mix
Kit (Applied Biosystems, Foster City, CA). QRT-PCR for LMP2A
was performed as described in Bell et al. [18] except that total cDNA
was used for PCR. Expression levels of viral and cellular genes were
normalized to actin unless otherwise specified. For miRNA quantifica-
tion,miScript Reverse Transcription kit andmiScript SYBRGreen PCR
Kit (Qiagen) were used according to the manufacturer’s instructions.
The in-house designed miRNA specific primer sequences are listed in
SI Methods. Expression levels of miRNA were normalized to RNU6B
snRNA. Analysis of each sample was performed in triplicate.
In Vitro Assay for Drosha Complex Digestion
The digestion substrate was prepared by in vitro transcription from
a T7-added miR-BART22 PCR product (∼300 nt) using MAXIscript
kit (Ambion). The primer sequences are listed in SI Methods. For
in vitro digestion, Drosha and Flag-DGCR8 expression vectors [19]
were cotransfected into 293FT cells at a 2:1 ratio. The Drosha/DGCR8
enzymatic complex was purified using the Flag-Tagged Protein im-
munoprecipitation kit (Sigma, St Louis, MO) 48 hours after trans-
fection. Digestion was performed by mixing 100 ng of RNA with
the precipitated complex at 37°C for 1.5 hours. Digested products were
visualized on 8% PAGE with SYBR Gold staining (Invitrogen) and
Northern blot analysis.
Target Prediction
To obtain more putative targets, we loosened the stringency in
MiRanda prediction by adjusting the energy threshold to −15 kcal/mol
and the cutoff score to 90. We used default settings for the RNAhybrid
program prediction. The LMP2A reference sequence for target predic-
tion was extracted from the National Center for Biotechnology Informa-
tion (AB290724).
Luciferase Reporter Assay
293FT cells (1 × 105) grown in 24-well plates were cotransfected with
miRNA and reporter constructs for analysis. Cells were harvested after
2 days for luciferase activity analysis using Dual Luciferase Reporter Kit
(Promega) as described previously [15]. See SIMethods for the details of
transfection.
Immunohistochemical Staining of LMP2A
Immunohistochemical (IHC) staining was performed by modified
methods as previously described [20]. In brief, the paraffin sections
were dewaxed in xylene and rehydrated in ethanol and peroxidase-
blocked with 3% H2O2 in room temperature for 20 minutes. Antigen
retrieval was performed by using pressure cooker with 10 nM citrate
buffer (pH 6.0) for 4 minutes. Primary antibody against LMP2A
(1:50 dilution, 15F9; AbD SeroTec, Raleigh, NC) was applied and
incubated for 2 hours. The section was incubated with biotinylated
secondary antibody (1:100 dilution; DAKO, Glostrup, Denmark) for
1 hour. The signal was visualized by using DAB Detection Kit (Sigma).
The presence of the EBV in the paraffin sections was confirmed by
EBER in situ hybridization, which carried out with an EBV probe
ISH kit (Novocastra, Newcastle, UK).
Western Blot Analysis
Western blot analysis was performed as previously described [15].
The primary antibodies used were LMP2A (1:2000 dilution, 15F9;
AbD SeroTec), AKT (1:1000 dilution; Cell Signaling Technology,
Danvers, MA), phospho-AKT (ser473; 1:1000; Cell Signaling). EGFP
Table 1. Sequence and Genomic Location (AJ507799) of EBV Encode RNA Not Matching to Known miRNA.
RNA Fragment Sequence (5′–3′) Length C666-1 X2117 Position
Group 1 miR-BART21 CACUAGUGAAGGCAACUAAC 20 1 0 145515:145534
Group 2 miR-BART22 UUACAAAGUCAUGGUCUAGUA(GU)* 21-23 14 1 147203:147215
Group 3 EBER1-5′ (A)AGGACCUACGCUGCCCU(A) 17-19 8 0 6629:6646
EBER1 GACUCUGCUUUCUGCCGU 18 1 0 6742:6759
EBER1 GGGAGGUUCUCUCGGGGCCACGCC 24 1 0 6659:6676
EBER1 3′ (UACC)AGCUGGUGGUCCGCAUGUUU 20-24 5 1 6772:6794
EBER2 UAGUGGUUUCGGACACAC 18 1 0 6972:6989
EBER2 GAGAAGGGUAUUCGGCUUGU 20 2 0 7098:7117
EBER2 AGGACAGCCGUUGCCCUAGUGGUUU 25 0 1 6956:6980
Sequence variations of the cloned fragments are indicated by parentheses.
*Of 15 sequences, 2 had two nucleotides shorter.
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(1:20,000 dilution; Clontech) and β-actin (1:30,000 dilution; Sigma).
All horseradish peroxidase–conjugated secondary antibodies used were
purchased from DAKO (1:20,000 dilution). The density of Western
blot signals was measured by Image J software.
Results
Identification and Expression of Novel EBV-Encoded
miRNA in NPC
Two independent cDNA libraries were constructed from C666-1
and X2117 cells. A total of 2928 clones with sequences longer than
18 nucleotides were obtained, including 1813 clones from C666-1
and 1115 clones from X2117 (Table W1). The known miRNA and
human sequences were annotated by blasting individual extracted
sequences against miRBASE [21] and GenBank databases. Sequences
that matched the EBV genome were identified from BLAST search
against the full-length EBV genome (accession number: AJ507799).
In the C666-1 library, 615 and 277 clones were matched to
known EBV and human miRNA, respectively, based on miRBase
(Version 11.0) search. In addition to the known miRNA, 811 clones
were human sequences that mostly corresponded to rRNA and tRNA
fragments. Of interest, 32 sequences that aligned to the EBV genome
showed no match to any known miRNA previously reported in lym-
phoid cells. According to their sequence similarity, these novel EBV
transcripts could be classified into three groups (Table 1). Groups 1
and 2 represented EBV fragments at positions 145515-145534 and
147203-147215, respectively. Group 3 contained multiple short EBV
fragments with homology to EBERs. Their sequences and cloning
Figure 1. Hairpin structures and expression of novel ebv-miRNA. (A) Stem-loop structures of miR-BART21 and miR-BART22 are illustrated.
The cloned mature miRNA sequences are indicated by underlining. The folding energy (dG) and EBV genomic sequences are listed below
the figures. (B) Representative Northern blot for cell lines, NPC xenografts and NPC biopsies showing the expression of miR-BART21 and
miR-BART22 are displayed. The normal epithelial cell line NP460 was included as a negative control. U6 RNA or SYBR Gold staining PAGE
was used to control for RNA loading. The miRNA expression in the same sample was assayed by QRT-PCR and was compared with C666-1
(set at 100). The analysis of each sample was performed in triplicate with the mean ± SD shown.
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frequency are listed in Table 1. Distribution of small RNA in the X2117
library was similar to C666-1, excepted that a higher percentage of hu-
man cellular miRNA was found in X2117 (Table W1). On the whole,
the most abundant EBV miRNA cloned were miR-BART9 (n = 467)
and miR-BART10 (n = 251). However, miR-BART15 and miR-
BART20 were not detected in our study. In fact, our previous
study suggested that miR-BART15 was undetectable by Northern blot
in all native infected, reinfected epithelial cell lines as well as in HeLa
cells overexpressing EBV RNA transcripts from the C666-1 strain
[12]. Nevertheless, Cosmopoulos et al. [22] have recently reported
the detection of BART15 and BART20 expression in C666-1 cell using
real time RT-PCR method.
To establish whether some of the isolated RNA fragments could
represent potential novel ebv-miRNA, putative precursor sequences
with sizes of around 70 nucleotides contained the cloned fragments
from the EBV genome were subjected to structure predictions using
the MFOLD program [17]. A precursor miRNA (pre-miRNA) hairpin
structure was produced from each of the putative precursor sequences
fromGroups 1 and 2 EBV fragments, which now namedmiR-BART21
and miR-BART22, respectively (Figure 1A).
The expressions of miR-BART21 and miR-BART22 in EBV-
infected NPC tumors were validated by Northern blot. The cell line
C666-1, three xenografts (X666, X2117, C15) and two primary tumor
biopsies were examined. The EBV-negative immortalized normal naso-
pharyngeal epithelial cell, NP460, was included as negative control.
EBV-positive lymphoid cell lines Akata, Namalwa, and Raji were also
examined for comparison. Expression of miR-BART21 was detected
in C666-1, X666, X2117, and one of the two primary NPC biopsies
(Figure 1B, upper panel ). In contrast, miR-BART22 was expressed in all
EBV-positive cells and particularly highly in NPC samples (Figure 1B,
lower panel ). These results suggested that the two novel EBV miRNA
were preferentially expressed inNPC cells. Because only a small amount
of RNA could be isolated from the primaryNPCbiopsies, we designed a
sensitive QRT-PCR assay for the detection of these novel EBV miRNA
in tissue specimens. The relative expression levels of miR-BART21 and
miR-BART22 in cell lines and xenografts as measured by QRT-PCR
were similar to those determined by Northern blot analysis (Figure 1B).
By using QRT-PCR, we confirmed high and consistent expression of
these two EBV miRNA in primary NPC tumors (Table 2).
Nucleotide Polymorphism Is Important for Drosha Processing
of miR-BART22
Because pre–miR-BART10 (AJ507799; 147304-147380) and pre–
miR-BART22 (147161-147231) are in close proximity in the EBV
genome, miR-BART10 and miR-BART22 are thought to share the
same RNA transcript in miRNA biogenesis. However, the expression
ratio ofmiR-BART22 tomiR-BART10was significantly higher inC666-
1 than Namalwa cells (P < .05) in both Northern blot analysis and
QRT-PCR analysis (Figure 2). This observation suggests that the bio-
genesis of miR-BART10 and miR-BART22 differs between these two
cell types. To evaluate if nucleotide variation(s) plays a role in the bio-
genesis of these novel miRNA, the flanking sequences of miR-BART21
and miR-BART22 from C666-1 (EU828629) and Raji (AJ507799)
were compared. We deployed the Raji-EBV sequence for analysis be-
cause Raji is commonly accepted as reference EBV sequence. On the
basis of matching analysis, we found two nucleotide variations in miR-
BART21 and four nucleotide changes in miR-BART22 (Figure 3A).
By MFOLD analysis, the predicted secondary structures of the miR-
BART21 primary transcript (∼300 nucleotides; pri-miR-BART21)
from Raji-EBV and C666-EBV strains were highly similar. In contrast,
the secondary structure predicted for miR-BART22 was dissimilar be-
tween the Raji-EBVand C666-EBV sequences. Folding predictions for
Table 2. Expression of Novel ebv-miRNA and LMP2A in NPC Samples.
Sample BART21 BART22 LMP2A mRNA* LMP2A IHC†
C666-1 100 100 100 −
NPC1 9.17 36.39 <1 −
NPC2 52.57 123.18 226 −
NPC3 31.85 41.07 242 −
NPC4 26.97 18.85 258 −
NPC5 47.44 76.54 257 −
NPC6 3.15 2.06 <1 +
NPC7 29.36 39.17 233 −
NPC8 25.81 28.05 335 +
NPC9 8.71 30.68 264 −
NPC10 61.72 64.04 NA −
NPC11 12 55.2 183 +
NP1 0 0 0 −
NP2 0 0 0 −
NP3 0 0 0 −
Expression level of C666-1 was set at 100.
NA indicates not analyzed.
*Expression level was normalized to EBNA1.
†LMP2A-negative (−) or-positive (+) were indicated.
Figure 2. miR-BART10 and miR-BART22 expression in C666-1 and
Namalwa cells. (A) Northern blot analysis demonstrates that the ex-
pression of miR-BART22 is significantly higher than miR-BART10 in
C666-1 (P < .05) but not in Namalwa cells. Representative results
from three independent experiments are shown. The relative expres-
sion level for each miRNA is calculated with reference to Namalwa
(set as 1) after normalization with U6 level. (B) Expression ratio of
miR-BART22 to miR-BART10 is significantly higher in C666-1 than
in Namalwa cells as measured by QRT-PCR (P < .05). The expres-
sion of miR-BART22 is compared with miR-BART10 after normaliza-
tion with EBNA1. The results shown are the mean ± SD from three
independent experiments.
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pri-miR-BART22 (147137:147456) from Raji-EBV suggested the
presence of a small side-branched stem-loop adjacent to the mature
miR-BART22 sequence (Figure 3B, left panel ). However, this stem-
loop was not predicted for the C666-EBV derived miR-BART22
sequence (Figure 3B, middle panel ). It is plausible that the nucleotide
variations found in the C666-EBV associated miR-BART22 underlie
the distinct structural difference predicted between the EBV strains.
Although all four nucleotide variations in miR-BART22 are positioned
distal from the hairpin structure, changes of two nucleotides (147144
A > Tand 147146 C > A) could readily affect the stem-loop formation
(Figure 3B, right panel ). Remarkably, these two specific nucleotide vari-
ations were identified in all 17 primary tumors tested fromHong Kong
NPC patients (Figure W1). According to the “junction anchoring”
model proposed for pri-miRNA processing [23], formation of the
Figure 3. The nucleotide polymorphisms in pri-miR-BART-21 and 22 from C666-1-EBV. (A) The nucleotide variations in pri-miR-BART21
(AJ507799, 145435:145614; left) and pri-miR-BART22 (147126:147305; right) are shown in shaded color. The mature miRNA sequences
are shown in gray boxes. (B) The predicted secondary structures of C666-1-EBV miR-BART22 (EU828629, 8087:8267; left), Raji-EBV
miR-BART22 (AJ507799, 147137:147456; middle), and the two nucleotide variations of Raji-EBV, Raji-EBV-2nt mut (147144 A > T
and 147146 C > A; right) are shown. The folding energy (dG) with units (kcal/mol) is indicated. (C) In vitro Drosha/DGCR8 processing
of the pri-miR-BART22 transcript. C666-1-EBV and Namalwa-EBV pri-miR-BART22 transcripts (pri-RNA) (AJ507799, 147137:147456) were
in vitro–transcribed and incubated with bead-bound Flag-tagged Drosha/DGCR8 complex (+) or beads containing empty vector transfected
cell extract (−). The digested products were separated on 8% PAGE for analysis (left). The presence of pre-miR-BART22 with a size around
70 nt was confirmed by Northern blot with a miR-BART22 complementary oligonucleotide probe (right). The representative result from at
least three individual blots is shown in panel C.
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small-side stem-loop could impair miRNA maturation by concealing
the DGCR8 recognition site during pri-miRNA processing. To elu-
cidate whether this nucleotide polymorphism of pri-miR-BART22
affects miRNA maturation, we examined the digestion efficiency of
Drosha/DGCR8 enzymatic complex by incubating immunopre-
cipitated flag-tagged Drosha/DGCR8 with in vitro–transcribed EBV
RNA substrates (147137-147456) from C666-1 and Namalwa
EBV genome, which share the same polymorphism as Raji (FigureW1).
PAGE analysis showed digested products of ∼70 bp, which could indi-
cate the presence of either miR-BART10 or miR-BART22 pre-miRNA
(Figure 3, B and C ). To further confirm that the digested product
contained pre-miR-BART22, Northern blot analysis with a com-
plementary miR-BART22 oligonucleotide was carried out on the
membrane-transferred PAGE gel. We found that in vitro digestion of
pre-miR-BART22 from C666-1 was much facilitated in Drosha/
DGCR8 processing compared with Namalwa (Figure 3C). Our find-
ings lead us to hypothesize that nucleotide polymorphisms within the
pri-miR-BART22 transcript can augment its maturation in NPC
and explain at least in part the varying transcript levels in different
EBV strains.
LMP2A Is a Potential Target of miR-BART22
We attempted prediction of potential viral and cellular targets of
miR-BART21 and miR-BART22 by MiRanda [24,25] and RNA-
hybrid [26] programs using standard parameters. A number of potential
cellular mRNA targets were suggested (Table W2), although many
failed to be validated by luciferase reporter assay (data not shown). How-
ever, we found a putative miR-BART22 binding site in the LMP2A-3′
UTR (AJ507799; 5546:5568). The predicted putative LMP2A-3′UTR
target site was highly conserved between different EBV strains (Fig-
ure W2). A total of 16 nucleotides including the seed sequences (2-
8 nt) of miR-BART22 are perfectly complementary to the target site
Figure 4. Viral LMP2A is a potential target ofmiR-BART22. (A) Base complementarity suggests that the putativemiR-BART22 target site is in
the 3′UTR of LMP2A (AJ507799, 5545:5568; upper). The wild-type (LMP2A-WT), truncated (LMP2A-M1) and mutated (LMP2A-M2 and -M3)
LMP2A sequences are shown. The seed-binding region is underlined and the base substitutions aremarked in red (lower). (B) The sequences
of miRNA mimics are displayed. The base substitutions made to restore seed mutant complementarity are labeled in red (miR-M2-BART22
and miR-M3-BART22). The relative firefly luciferase activity was normalized to the renilla luciferase control, and results were taken from at
least three independent experiments. Data shown are the mean ± SD. Statistical analysis by Student’s t test was used. **P < .001.
1180 Modulation of LMP2A by miR-BART22 Lung et al. Neoplasia Vol. 11, No. 11, 2009
(Figure 4A). To study the predicted suppressive effect of miR-BART22
on LMP2A, a series of dual luciferase reporter assays were performed in
293FT cells. The reporter constructs contained synthetic oligonucleo-
tides of the predicted or mutated binding sequence cloned into the 3′
UTRof pMIR-REPORT plasmid. Using amiRNA expression vector in
reporter assays, we found that miR-BART22 exerted strong inhibitory
effect on the LMP2A 3′UTR (42%, P < .001). Nevertheless, repression
was eliminated when the complementarities of the seed region were
either deleted or mutated, LMP2A-M1-M3 in Figure 4A. This observa-
tion suggested that the repressive property of BART22 on the LMP2A
3′UTR was both functional and specific.
To further confirm the importance of seed sequence complemen-
tarity in the BART22-LMP2A interaction, we performed additional
luciferase assays using LMP2A-M1-M3 reporter plasmids with miR-
BART22 and two miRNA mimics, miR-M2-BART22 and miR-M3-
BART22, designed to compensate for the mutated seed regions of
the LMP2A-M2 and M3 reporters (Figure 4B). The miRNA mimics
exerted differing levels of suppression with the BART22 3′UTR, indi-
cating that the miRNA mimics were functionally active. However, in
cotransfectionwith the LMP2A-WT3′UTR reporter, onlymiR-BART22
was able to successfully reduce translation. Although seed binding
may be critical for initiating repression, mutant miR-M3-BART22
with restored complementarity to LMP2A-M3 failed to exert an inhib-
itory effect on its corresponding mutated reporter. Whereas miR-M2-
BART22 significantly inhibited translation of the LMP2A-M2mutated
reporter, it expressed only slightly below the control level and clearly
did not exhibit a profound repression ability (Figure 4B). Together,
our data suggest that the seed interaction between miR-BART22 and
LMP2A-3′UTR is unique and that replacing seed pairing with other
complementary sequences yields negligible or only partial suppressive
effects.We further investigated whether LMP2A-3′UTRmight contain
binding sites for other miR-BARTs. By loosening theMiRanda program
parameters for prediction, target sites for miR-BART1, 12, 14, and 16
were suggested but none could be successfully validated by luciferase
reporter assay (Figure W3). This further suggests the uniqueness of
the interaction between miR-BART22 and the LMP2A-3′UTR and
thus of the controlled expression of LMP2A.
Differential Expression of LMP2A in NPC
To investigate whether LMP2A is commonly expressed in NPC, we
performed both RT-PCR andWestern Blot on a panel of NPC samples
from Southern China. Although the LMP2A RNA transcript could be
detected in C666-1 cells and in NPC xenografts X666 and X2117,
none of them showed detectable LMP2A protein levels in Western
blots (Figure W4). Nevertheless, we were able to detect weak focally
expressed LMP2A in X2117 by IHC. As a control, strong LMP2A
staining was demonstrated in an EBV-positive IM and six of the eight
HD biopsies. This finding suggested that IHC analysis has a higher
sensitivity for detection of LMP2A expression. By IHC, we were able
to detect weak LMP2A expression in 6 (23%) of 26 primary NPC
tumors (Figure 5). The expression levels of miR-BART22 and LMP2A
mRNA have also been determined in ten of these tumors (Table 2).
Figure 5. LMP2A protein expression in NPC, IM, and HD specimens. Upper panel: EBV-positive NPC cell line and xenografts. LMP2A
expression was not detected in NPC cell line C666-1 and xenograft X666. Only weak and focally LMP2A expression was detected in
xenograft X2117. Middle panel: Primary NPC biopsies. Weak expression of LMP2A was noted in three NPC samples (NPC6, 8, 11). A
negative example (NPC2) was included. Lower panel: IM and HD. Strong LMP2A expression was detected in IM. Three positive exam-
ples of HD were included.
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Interestingly, the LMP2A mRNA expression level did not directly cor-
relate with the protein expression, and relatively low expression levels
of miR-BART22 miRNA were observed in all three LMP2A-positive
primary tumors, as well as in X2117 (NPC6, 8, and 11 in Table 2 and
Figure 5). This finding supports the possible regulatory role of miR-
BART22 in LMP2A expression.
Suppression of LMP2A Protein Expression by miR-BART22
To establish the strong interaction between miR-BART22 and the
LMP2A-3′UTR, two supportive experiments were designed. First, the
dose effect of miR-BART22 on LMP2A expression was studied by
cotransfection of different amounts of miR-BART22 with the LMP2A
expression vector that included the full length of LMP2A 3′UTR.MiR-
BART22 suppressed the LMP2A protein level in a dose-dependent
manner without an apparent effect on LMP2A mRNA levels (Fig-
ure 6A). MiR-BART22 expression had also no obvious effect on the
EGFP control protein. Second, transfection of miR-BART22 into
HEK293 cells that had been stably transfected with pcDNA3.1-
LMP2A (Figure 6B) readily suppressed levels of the LMP2A protein.
The transfection again had no significant effect on LMP2A mRNA
expression. These results strongly suggest that LMP2A is a direct target
of miR-BART22, which specifically represses LMP2A expression at the
posttranscriptional level.
Discussion
Besides the production of viral latent proteins, it is believed that EBV
contributes to NPC development through expressing abundant non-
coding viral RNA, including EBERs and miRNA. In this study, we
report the identification of two new ebv-miRNA, miR-BART21 and
miR-BART22, from screening 2928 clones by traditional small RNA
library cloning method in the NPC cell line and xenograft. These
two newly identified miRNA are consistently expressed in NPC cells
and primary tissues. In line with our finding, Zhu et al. [27] have re-
cently reported the identification of several novel EBV miRNA by
massive sequencing of 47,000 clones that were derived from two NPC
biopsies. We note that two identified EBV miRNA from their study,
ebv-miR-BART21-3p and ebv-miR-BART22, are identical in sequence
to our newly discovered miR-BART21 and miR-BART22, respectively.
Our study clearly establishes the relevance of miR-BART21 and miR-
BART22 in NPC and demonstrates the feasibility of direct cloning of
small cDNA libraries as an efficient approach for novel discovery of
viral miRNA.Nevertheless, the study byMeister’s group failed to address
Figure 7. Function of ebv-BART-miRNA on host cell survival. miR-
BART1, 16, and 17 can regulate the viral LMP1 protein expression
[12] and miR-BART5 can alter the expression of the p53-upregulated
modulator of apoptosis (PUMA) [13]. And in this article, miR-BART22
is demonstrated as a modulator of the viral gene, LMP2A.
Figure 6. Suppression of LMP2Aprotein expressionbymiR-BART22.
(A) Western blot of LMP2A and EGFP in 293FT cells transiently co-
transfected with 0.1 μg per well pEGFP-C1 plasmid in six-well plate
format, the amount of expression plasmids as indicated (lanes 3-6),
and 2 μg of total DNA made up with pcDNA3.1 as carrier. LMP2A
expression level was normalized to EGFP. miR-BART22 and LMP2A
RNA expression levels in the same sample were analyzed by QRT-
PCR and are shown relative to lane 3. (B) The representativeWestern
blot results indicate that miR-BART22 represses LMP2A expression
in HEK293-LMP2A stable clones. The stable clones transfected
with the siRNA control (siCtl) and LMP2A specified siRNA (siLMP2A)
were included as controls. The LMP2A expression level was normal-
ized to actin and the level relative to mock transfection (set at 1) was
calculated. LMP2A mRNA expression in the same sample was
assayed by QRT-PCR.
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the prevalence and functional implications of miR-BART21 and miR-
BART22 in NPC. In this study, we demonstrate the presence of a strain
specific EBV polymorphism that predisposes to the enhanced expression
of miR-BART22.
Of the two new ebv-miRNA, miR-BART22 was found to be highly
expressed in almost all NPC samples studied. We found polymor-
phisms in EBV strains from Southern China, especially at nt147144
A >Tand nt147146C > A, which favor the biogenesis ofmiR-BART22
and thus its expression level (Figure 3). Although the LMP2A trans-
cript was previously reported to be detected in most NPC samples
[20,28,29], our IHC data indicate only 23% of primary NPC tumors
from our locality have detectable LMP2A protein expression. Transcrip-
tional regulation of LMP2A in EBV-infected cells by epigenetic and
viral latent protein mechanisms has been reported previously [30–32].
In this study, we showed that LMP2A can also be modulated at the
translational level by miR-BART22. Moreover, whereas seed comple-
mentarity of the LMP2A-3′UTR with other known ebv-miRNA has
been suggested, we have not been able to confirm target association in
a reporter assay (FigureW3), implicating a unique role ofmiR-BART22
in the translational regulation of LMP2A. We were able to demonstrate
LMP2A protein expression in NPC biopsies, which tend to have rela-
tively low expression of miR-BART22 (Table 2). However, not all biop-
sies with low miR-BART22 expression have detectable LMP2A,
indicating that LMP2A expression might also be regulated by other
pathways. Such multiple regulatory mechanisms have also been impli-
cated in LMP1 modulation [12].
Previous reports suggested that expression of LMP2A can induce
AKT activity in C666-1 cells [33] and activate the Notch signaling
pathway in epithelial cells [34]. We showed that transient transfection
of miR-BART22 in LMP2A-expressing HEK293 stable clones could
suppress Notch-1 mRNA expression and mildly suppress AKT activa-
tion (Figure W5). Although suppression of both Notch and AKT path-
ways may not be in favor of cancer cell growth, forced expression of
miR-BART22 in normal epithelial cells did not induce any change in
cell proliferation (unpublished data). These observations are consistent
with the recent finding that overexpression of LMP2A in C666-1 cells
did not affect cell growth and migration, although it can activate the
PI3K/Akt pathway [33]. Thus, we believed that down-regulation of
LMP2A by miR-BART22 may contribute to cancer development by
other means, such as permitting the escape of infected cells from the
host immune surveillance.
The potential benefits of suppressing LMP2A expression during
NPC development can be many. Previous reports showed that NPC
cells are capable of processing and presenting endogenously synthesized
proteins toCTLs. LMP2A, in particular, has a stronger immunogenicity
than two other NPC expressed viral genes, namely, EBNA1 and LMP1
[29,35–37]. In this regard, limiting LMP2A protein expression would
have potential advantages for NPC cells to escape host immune sur-
veillance, and thus, LMP2A expression in NPC is predictably low. In
fact, immunomodulatory effects of other ebv-miRNA have recently
been demonstrated. For example, down-regulation of LMP1 expression
by miR-BARTs may favor immune escape by decreasing the antigen-
processing function of NPC cells [12]. In primary effusion lymphoma,
miR-BHRF1-3 can target CXCL-11/I-TAC, an IFN-inducible T-cell
attracting chemokine [38]. Furthermore, miR-BART2-5p can repress
the expression of the cellular stress–induced immune molecule, MICB
[39]. Apart from immunogenicity, LMP2A, as opposed to LMP1,
could suppress nuclear factor-κB levels resulting in an antiproliferative
effect [40]. Moreover, LMP2A-expressing epithelial cells could also
inhibit telomerase reverse transcription activity, an enzyme important
for cell immortalization and transformation [41]. Because LMP2A has
diverse functional roles in epithelial cells, its expression level is there-
fore required to be tightly regulated during the development of NPC.
Our group has previously reported that miR-BARTs regulate LMP1
expression [12] and that miR-BART5 affects the expression of the
cellular target gene PUMA [13]. In this study, we further identified
miR-BART22 as a modulator of an important oncogenic and immuno-
genic viral gene, LMP2A (Figure 7). In concordance with our previous
reports, we have thus provided evidence for the vital roles of EBV-
encoded miRNA in regulating oncogenic and immunogenic viral latent
protein expression, which holds importance in the progression and
survival of EBV-infected NPC.
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SI Methods
Plasmid constructs. The miRNA expression plasmids were made by
inserting the PCR product that contains miRNA flanking sequence
(∼300 nt) into pcDNA3.1 expression vector through Hind III and
either XbaI or XhoI sites. All the PCR products were generated using
C666-1 DNA as template, and the primer sequence used for PCR am-
plification are listed below:
BART1-F: 5′-GGTAAGCTTATGCTGCTGGTGT-3′;
BART1-R: 5′-GGCTCTAGATGGTCATGTTTCCCT-3′;
BART14-F: 5′-GGTAAGCTTGGACGGCTGAC-3′;
BART14-R: 5′-GGCTCTAGAAAAGGCCTGCTGT-3′;
BART16-F: 5′-GGTAAGCTTCTGATGCTCTGTGG-3′;
BART16-R: 5′-GGCTCTAGATGGATTGGACCAAC-3′;
BART21-F: 5′-AGCCAAGCTTGCTGGGCAGAGAA-
TGTTTGT-3′;
BART21-R: 5′-ACCGCTCGAGTAAGGGGAGGGGAAAGC-
TAAA-3′;
BART22-F: 5′-AGCCAAGCTTACTTCATGGGTCCCG-
TAGTG-3′;
BART22-R: 5′-ACCGCTCGAGCCACACTGCTAAGG-
CAGTCA-3′.
The pcDNA3.1-LMP2A expression plasmid was constructed by
inserting 2 kb of RT-PCR product that included a complete LMP2A
ORF and 3′UTR into pcDNA3.1 expression vector through EcoRI
and XbaI sites. The RT-PCR product was amplified from RNA in
B95-8 cells by using the LMP2A-F primer: 5′-ACG GAA TTC TGC
TGC AGC TAT G-3′ (EBV coordination: 166092-166105) and
LMP2A-R primer: 5′-CGT TCT AGA GCA CAT TGG GTT TAT
TGG-3′ (EBV coordination: 5840-5856). The presence of LMP2Acod-
ing sequence and the complete 3′UTR was confirmed by sequencing.
Construction of firefly luciferase reporter vector was described pre-
viously [1]. In brief, two micrograms of sense (S) and antisense (AS)
oligonucleotides that encoded a single-miRNA tested target were
annealed in 30 mM HEPES buffer (pH 7.4) containing 100 nM
potassium acetate and 2 mM magnesium acetate and cloned down-
stream of the cytomegalovirus (CMV) promoter-driven firefly luciferase
cassette in a pMIR-REPORT vector (Ambion, Inc) through SpeI and
HindIII sites. The sequences of oligonucleotides used for cloning are
listed as below:
T1-S: 5′-CTAGTGATCGCCTGCCACTTCCACAGCAA-3′
T1-AS: 5′-AGCTTTGCTGTGGAAGTGGCAGGCGATCA-3′
T2-S: 5′-CTAGTAACCCCACGGAGCAGGGCAACATTG-
CAGGGA-3′
T2-AS: 5′-AGCTTCCCTGCAATGTTGCCCTGCTCCGT-
GGGGTTA-3′
T3-S: 5′-CTAGTAGACTATGCATACACTGAATTTAGA-3′
T3-AS: 5′-AGCTTCTAAATTCAGTGTATGCATAGTCTA-3′
T4-S: 5′-CTAGTAGACCTGTGTGCTGTATTTAA-3′
T4-AS: 5′-AGCTTTAAATACAGCACACAGGTCTA-3′
BART12-S: 5′-CTAGTAACCACACCAAACACCACAGGAA-3′
BART12-AS: 5′-AGCTTTCCTGTGGTGTTTGGTGTGGTTA-3′
BART14-S: 5′-CTAGTATCCCTACTACTGCAGCATTTAA-3′
BART14-AS: 5′-AGCTTTAAATGCTGCAGTAGTAGGGATA-3′
BART16-S: 5′-CTAGTAGAGCACACACCCACTCTATC-
TAAA-3′
BART16-AS: 5′-AGCTTTTAGATAGAGTGGGTGTGTGC-
TCTA-3′
BART21-S: 5′-CTAGTGTTAGTTGCCTTCACTAGTGA-3′
BART21-AS: 5′-AGCTTCACTAGTGAAGGCAACTAACA-3′
BART22-S: 5′-CTAGTACTACTAGACCATGACTTTGTAAA-3′
BART22-AS: 5′-AGCTTTTACAAAGTCATGGTCTAGTAGTA-3′
BART1-5p-S:5′-CTAGTCACAGCACGTCACTTCCACTAAGAA-3′
BART1-5p-AS: 5′-AGCTTTCTTAGTGGAAGTGACGTGC-
TGTGA-3′
LMP2A-WT-S: 5′-CTAGTCCTGTGTGACCCCTCACTTT-
GTACA-3′
LMP2A-WT-AS:5′-AGCTTGTACAAAGTGAGGGGTCACA-
CAGGA-3′
LMP2A-M1-S: 5′-CTAGTCCTGTGTGACCCCTCAA-3′
LMP2A-M1-AS: 5′-AGCTTTGAGGGGTCACACAGGA-3′
LMP2A-M2-S: 5′-CTAGTCCTGTGTGACCCCTCAGTAT-
CTTCA-3′
LMP2A-M2-AS: 5′-AGCTTGAAGATACTGAGGGGTCACA-
CAGGA-3′
LMP2A-M3-S: 5′-CTAGTCCTGTGTGACCCCTCACATA-
GAAGA-3′
LMP2A-M3-AS: 5′-AGCTTCTTCTATGTGAGGGGTCACA-
CAGGA-3′
Transfection for luciferase analysis. Cells grown in 24-well plates
were cotransfected with miRNA and reporter construct for analysis.
All miRNA expression plasmid transfection experiments were carried
out by GeneJuice transfection reagent (Novagen). Transfection complex
containing 50 ng of reporter plasmid, 2 ng of pRL-CMV control report-
er plasmid, and 200 ng of indicatedmiRNA expression plasmidwas pre-
pared for each transfection. For miRNA mimic transfection, a mixture
containing 50 nMof miRNAmimic, 800 ng reporter vector, and 80 ng
control reporter vector was prepared with Lipofectamine 2000 (Invitro-
gen). The luciferase activities were assayed by Dual Luciferase Reporter
Kit (Promega). Three separate experiments were performed, and
Student’s t test was used for statistical analysis. P < .05 was considered
as statistically significant.
Others oligonucleotide sequences used in this study
Northern blot:
BART10 NB: 5′-TGTACAGAACCAAAGAGGTGGC-3′
BART21 NB: 5′-GTTAGTTGCCTTCACTAGTG-3′
BART22 NB: 5′-ACTACTAGACCATGACTTTGTAA-3′
U6NB: 5′-GCAGGGGCCATGCTAATCTTCTCTGTATCG-3′
In vitro transcription PCR:
T7-C666-BART22-F: 5′-TAATACGACTCACTATAGGGC-
TAATATCA-3′
T7-Nam-BART22-F: 5′-TAATACGACTCACTATAGGGCTA-
ATAACC-3′
T7-BART22-R: 5′-CCCAAGGCAGGTAAACATTG-3′
RT-PCR for LMP2A and actin:
LMP2A-Exon 1-F: 5′-CGGGATCACTCATCTGAACACATA-3′
LMP2A-Exon 3-R: 5′-CATGTTAGGCAAATTGCAAA-3′
Actin-207F: 5′-TAAGGAGAAGCTGTGCTACGTC-3′
Actin-207R: 5′-GGAGTTGAAGGTAGTTTCGTGG-3′
QRT-PCR (miRNA):
BART10: 5′-TACATAACCATGGAGTTGGCTGT-3′
BART21: 5′-CACTAGTGAAGGCAACTAAC-3′
BART22: 5′-TTACAAAGTCATGGTCTAGTAGT-3′
snU6: 5′-ACGCAAATTCGTGAAGCGTT-3′
QRT-PCR (SYBR Green):
Actin 69F: 5′-CTGGCACCCAGCACAATG-3′
Actin 69R: 5′-GCCGATCCACACGGAGTACT-3′
EBNA1-1162F: 5′-TCATCATCATCCGGGTCTCC-3′
EBNA1-1229R: 5′-CCTACAGGGTGGAAAAATGGC-3′
EGFP 82F: 5′-CGACAACCACTACCTGAGCA-3′
EGFP 82R: 5′-GAACTCCAGCAGGACCATGT-3′
Notch 1-F: 5′-CCGCAGTTGTGCTCCTGAA-3′
Notch 1-R: 5′-ACCTTGGCGGTGTCGTAGCT-3′
QRT-PCR for LMP2A [2]:
LMP2A-Exon 1-F: 5′-CGGGATCACTCATCTGAACACATA-3′
LMP2A-Exon 2-R: 5′-GGCGGTCACAACGGTACTAACT-3′
TaqMan Probe: (FAM)-CAGTATGCCTGCCTGTAATTGT-
TGCG-(TAMRA)
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Table W1. Distribution of Small RNA from Cloned Libraries.
C666-1 X2117
Human sequences 812 167
Total known hsa-miRNA 277 433
Total known ebv-miRNA* 615 504
BART1-5p (−3p) 25 (9) 6 (2)
BART2-5p 1 0
BART3-3p (−5p) 30 (11) 6 (1)
BART4 11 2
BART5 22 5
BART6-5p (−3p) 18 (17) 0 (0)
BART7 45 64
BART8 (8*) 15 (7) 16 (10)
BART9 179 288
BART10 169 82
BART11-5p (−3p) 7 (4) 0 (0)
BART12 6 1
BART13 (13*) 1 (0) 3 (1)
BART14 (14*) 5 (2) 0 (2)
BART16 7 0
BART17-3p (−5p) 14 (9) 6 (0)
BART18-5p 1 0
BART19-3p (−5p) 0 (0) 8 (1)
EBV fragments (Group 1)† 1 0
EBV fragments (Group 2)‡ 14 1
EBV fragments (Group 3)§ 17 2
Total number of EBV fragments 32 3
Unknown sequences 77 8
Total clones for analysis 1813 1115
*All miR-BHRF1s, BART15, and BART20 were not cloned.
†miR-BART21 clones.
‡miR-BART22 clones.
§EBV sequences from EBERs.
Figure W1. Alignments of pri-miR-BART22 in different EBV strains. Alignment of pri-miR-BART22 (AJ507799, 147142:147227) in 17 NPC
samples (NPC-T1 to NPC-T17), EBV-infected cell lines, and NPC xenografts. The sequences of Raji (M35547), IM9 (EU828628), Mutu 1
(EU828632), and NPC samples GD1 (AY961628), and C18 (EU828627) were extracted from GenBank for analysis. The sequences of other
samples were directly obtained by sequencing in our laboratory. The two critical nucleotide variations for small side stem-loop formation are
shown inside the pink boxes.
Table W2. Examples of Predicted Cellular mRNA of miR-BART22.
*Gene symbol is indicated as recommended by HUGO.
Figure W3. Predicted miR-BARTs binding site on LMP2A 3′UTR. (A) Schematic diagram showing the location of predicted target site (t1-4)
on the 3′UTR of the LMP2A gene (open bar) according to GenBank accession no. AJ507799. (B) The alignment of the target sites to the
corresponding miR-BARTs is shown. The target sites were cloned into luciferase reporters for analysis. (C) Luciferase reporter assays of
t1-4 containing constructs in the presence of indicatedmiR-BARTswere performed in 293FT cells. Reporter activity was normalized to renilla
luciferase control. The luciferase activity from construct containing no miRNA target on 3′UTR (white bar) was set at 1. Data shown are the
mean ± SD from three independent experiments.
Figure W2. Conservation of the putative miR-BART22 binding site on the 3′UTR of the LMP2A gene in different EBV strains. Direct
sequencing results of the 3′UTR of the LMP2A gene from different samples are illustrated. B95-8 sequence is extracted from GenBank
(accession number: X01995) and is shown as a reference sequence.
Figure W4. Western blot analysis of LMP2A expression in NPC
samples. One NPC cell line (C666-1) and two NPC xenografts (X666
and X2117) were analyzed. Protein samples from LMP2A-transfected
293FTcells (293-LMP2A) andanEBV-negative epithelial cell line,NP69,
were included as the positive and negative controls, respectively.
The nonspecific bands (NS) are labeled. The LMP2A and EBNA1
mRNA expression levels in the same sample were confirmed by
RT-PCR andQRT-PCR, respectively. TheQRT-PCR results were nor-
malized to GAPDH and are shown asmean± SD from at least three
independent experiments. The expression levels of LMP2A in 293-
LMP2A and EBNA1 in C666-1 were set at 1.
Figure W5. Inhibition of LMP2A downstream effectors by miR-
BART22. (A) Inhibition of LMP2A-mediated AKT activity by miR-
BART22 was demonstrated using Western blot. HEK293-LMP2A
stable cells transfected with siRNA control (siCtl) and LMP2A specific
siRNA (siLMP2A) were included as controls. The representative blot
from three independent experiments is shown in panel A. The AKT
activity was calculated by the expression level of phosphorylated
AKT over total AKT and relative to control transfection (set at 1) is
shown. (B) The relative expressions of Notch-1 of these transfected
cells were analyzed by QRT-PCR. Notch-1 expression levels were
normalized to actin and were compared with the mock transfection
(set at 1). All data shown in the figure are the mean ± SD from three
independent transfection experiments. Statistical analysis by Stu-
dent’s t test was used and compared with the control transfection.
*P < .05; **P < .001.
